{"id":"aai101-i-v","_chembl":{"chemblId":"CHEMBL470883","moleculeType":"Small molecule","molecularWeight":"318.37"},"_dailymed":null,"_scrapedAt":"2026-03-28T04:51:20.095Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779123366,"model":"claude-sonnet-4-5-20250929"},"description":"AAI101 i.v. is an investigational intravenous therapy in Phase 1 clinical development by Allecra Therapeutics. The drug's molecular target, mechanism of action, and specific therapeutic indications have not been publicly disclosed. Early-stage clinical trials are evaluating its safety and tolerability profile.","indications":{"approved":[{"status":"investigational","condition":"Unknown","patientPopulation":"Unknown"}]},"trialDetails":[{"nctId":"NCT03685084","phase":"PHASE1","title":"Investigation of AAI101 Safety, Tolerability & PK in Healthy Volunteers","status":"COMPLETED","sponsor":"Allecra","startDate":"2013-10-10","conditions":"Healthy","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AAI101"],"phase":"phase_1","status":"active","brandName":"AAI101 i.v.","genericName":"AAI101 i.v.","companyName":"Allecra","companyId":"allecra","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":1,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}